Application of PEG-chitosan copolymers for regulation of catalytic properties of enzymes for medical application using recombinant Erwinia carotovora L-asparaginase as an example
Tóm tắt
A new approach to the regulation of catalytic properties of medically relevant enzymes has been proposed using the novel recombinant preparation of L-asparaginase from Erwinia carotovora (EwA), a promising antitumor agent. New branched co-polymers of different composition based on chitosan modified with polyethylene glycol (PEG) molecules, designated as PEG-chitosan, have been synthesized. PEG-chitosan copolymers were further conjugated with EwA. In order to optimize the catalytic properties of asparaginase two types of conjugates differing in their architecture have been synthesized: (1) crown-type conjugates were synthesized by reductive amination reaction between the reducing end of the PEG-chitosan copolymer and enzyme amino groups; (2) multipoint-conjugates were synthesized using the reaction of multipoint amide bond formation between PEG-chitosan amino groups and carboxyl groups of the enzyme in the presence of the Woodward’s reagent. The structure and composition of these conjugates were determined by IR spectroscopy. The content of the copolymers in the conjugates was controlled by the characteristic absorption band of C-O-C bonds in the PEG structure at the frequency of 1089 cm−1. The study of catalytic characteristics of EwA preparations by conductometry showed that at physiological pH values the enzyme conjugates with PEG-chitosan with optimized structure and the optimal composition demonstrated 5–8-fold higher catalytic efficiency (k
cat/K
m) than the native enzyme. To certain extent, this can be attributed to favorable shift of pH-optima in result of positively charged amino-groups introduction in the vicinity of the active site. The proposed approach, chito-pegylation, is effective for regulating the catalytic and pharmacokinetic properties of asparaginase, and is promising for the development of prolonged action dosage forms for other enzyme therapeutics.
Tài liệu tham khảo
Pui, C.H. and Evans, W.E., N. Engl. J. Med., 2006, vol. 354, pp. 166–178.
Redaelli, A., Laskin, B.L., Stephens, J.M., Botteman, M.F., and Pashos, C.L., Eur. J. Cancer Care, 2005, vol. 14, pp. 53–62.
Uren, J.R. and Hand Schumacher, R.E., in Cancer: A comprehensive treatise, vol. 5, Becker, F.F., Ed., New York: Plenum Press, 1977, pp. 487–557.
Papageorgiou, A.C., Posypanova, G.A., Andersson, C.S., Sokolov, N.N., and Krasotkina, J., FEBS J., 2008, vol. 17, pp. 4306–4316.
Taylor, C.W., Dorr, R.T., Fanta, P., Hersh, E.M., and Salmon, S.E., Cancer Chemother. Pharmacol., 2001, vol. 47, pp. 83–88.
Kobrinsky, N.L., Sposto, R., Shah, N.R., Anderson, J.R., DeLaat, C., Morse, M., Warkentin, P., Gilchrist, G.S., Cohen, M.D., Shina, D., and Meadows, A.T., J. Clin. Oncol., 2001, vol. 19, pp. 2390–2396.
Avramis, V.I., Kwock, R., Avramis, I.A., Cohen, L.J., and Inderlied, C., In Vivo, 2001, vol. 15, pp. 1–9.
Soares, A.L., Guimaraes, G.M., Polakiewicz, B., de Moraes Pitombo, R.N., and Abrahao-Neto, J., Inter. J. Pharm., 2002, vol. 237, pp. 163–170.
Roberts, M.J., Bentley, M.D., and Harris, J.M., Adv. Drug Deliv. Rev., 2002, vol. 54, 459–476.
Pasut, G., Sergi, M., and Veronese, F.M., Adv. Drug Deliv Rev., 2008, vol. 60, no. 1, pp. 69–78.
Moreadith, R.W. and Collen, D., Adv. Drug Deliv. Rev., 2003, vol. 55, pp. 1337–1345.
Ton, G.N., Fine, J.P., and Kwon, C.S., J. Control Release, 2005, vol. 104, pp. 129–139.
Cheng, P.N., Lam, T.L., Tsui, S.M., Cheng, A.W., Lo, W.H., and Leung, Y.C., Cancer Res., 2007, vol. 67, pp. 309–317.
Kieseier, B.C. and Calabresi, P.A., CNS Drugs, 2012, vol. 26, pp. 205–214.
Kuchumova, A.V., Krasotkina, Yu.V., Khasigov, P.Z., and Sokolov, N.N., Biomed. Khim., 2007, vol. 53, pp. 107–111.
Mozhaev, V.V., Kudryashova, E.V., Efremova, N., and Topchieva, I.N., Biotech. Techniques, 1996, vol. 10, pp. 849–854.
Abuchowski, A., Kazo, G.M., Verhoest, C.R., Jr., Van Es, T., Kafkewitz, D., Nucci, M.L., Viau, A.T., and Davis, F.F., Cancer Biochem. Biophys., 1984, vol. 7, pp. 175–186.
Dinndorf, P.A. Gootenberg, J., Cohen, M.H., Keegan. P., and Pazdur, R., Oncologist, 2007, vol. 12, pp. 991–998.
Lin, W.J. and Chen, M.H., Carbohydrate Polymers, 2007, vol. 67, pp. 474–480.
Kudryashova, E.V., Zorov, I.N., Vasil’eva, I.V., Sinitsyn, A.P., and Levashov, A.V., Bioorgan. Khim., 2009, vol. 35, pp. 1–8.
Borisova, A.A., Eldarov, M.A., Zhgun, A.A., Aleksandrova, S.S., Omel’yanyuk, N.M., Sokov, B.N., Berezov, T.T., and Sokolov, N.N. Biomed. Khim., 2003, vol. 49, pp. 502–507.
Sokolov, N.N., Eldarov, M.A., Sidoruk, K.V., Zhgun, A.A., Borisova, A.A., Aleksandrova, S.S., Omel’yanyuk, N.M., Bogush, V.G., Krasotkina, Yu.V., Gervasiev, Yu.V., Pokrovskaya, M.V., Sokov, B.N., Berezov, T.T., Skryabin, K.G., and Archakov, A.I., Mol. Meditsina, 2005, vol. 1, pp. 45–53.
Omel’yanyuk, N.M., Borisova, A.A., Aleksandrova, S.S., Pokrovskaya, M.V., Eldarov, M.A., Archakov, A.A., Skryabin, K.G., and Sokolov, N.N., Biotechnologiya, 2005, vol. 3, pp. 27–34.
Eldarov, M.A., Zhgun, A.A., Gervaziev, Yu.V., Aleksandrova, S.S., Omel’yanyuk, N.M., Archakov, A.A., Skryabin, K.G., and Sokolov, N.N., Rus. Patent no. 2221868, Byul. Izobret., 2004, no. 2.
Karasev, V.S., Bochkova, O.P., Chugunov, A.M., Melik-Nubarov, N.S., Grozdova, I.D., Chernovskaya, T.V., Denisov, L.A., Rudenko, E.G., Morozova, E,L., Bogush, V.G., Sidoruk, K.V., Koltun, I.O., Skatova, G.E., Abakumova, O.Yu., Podobed, O.V., and Sokolov, N.N., Rus. Patent no. 2441914, Byul. Izobret., 2010, no. 4.
Varlamov, V.P., Nemtsev, S.V., and Tikhonov, V.E., Khitin i khitosan: priroda, polychenie i primenenie (Chitin and Chitosan: Nature, Preparation and Application), Rus. Chitin Society, 2010.
Ozerin, A.N., Perov, N.S., Zelenetskii, A.N., Ozerina, L.A., Surin, N.M., Vladimirov, L.V., and Yurlovskaya, V.D. Rus Nanotekh., 2009, vol. 4, pp. 107–113.
Pasut, G. and Veronese, F.M., Adv. Drug Deliv. Rev., 2009, vol. 61, no. 13, pp. 1177–1188.